Influence of Cardiac Output on Peak t-PA Plasma Levels in Patients Receiving Thrombolytic Therapy with Recombinant Tissue-Type Plasminogen Activator – Correlation with Patency Rate

Kurt Huber; Renate Beckmann; Peter Probst; Friedrich Rauscha; Fritz Kaindl; Bernd R Binder

doi:10.1055/s-0038-1651546

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1993; 69(01): 045-049
DOI: 10.1055/s-0038-1651546

Original Article

Fibrinolysis

Schattauer GmbH Stuttgart

Influence of Cardiac Output on Peak t-PA Plasma Levels in Patients Receiving Thrombolytic Therapy with Recombinant Tissue-Type Plasminogen Activator – Correlation with Patency Rate

Authors

Kurt Huber

¹The Department of Cardiology, University of Vienna, Vienna, Austria

²The Department of Clin. Exp. Physiology, University of Vienna, Vienna, Austria
Renate Beckmann

²The Department of Clin. Exp. Physiology, University of Vienna, Vienna, Austria
Peter Probst

¹The Department of Cardiology, University of Vienna, Vienna, Austria
Friedrich Rauscha

¹The Department of Cardiology, University of Vienna, Vienna, Austria
Fritz Kaindl

¹The Department of Cardiology, University of Vienna, Vienna, Austria
Bernd R Binder

²The Department of Clin. Exp. Physiology, University of Vienna, Vienna, Austria

Abstract

PDF Download

Summary

We studied 35 consecutive patients with short onset of myocardial infarction who underwent thrombolytic therapy with rt-PA at a standard dosage regimen of 100 mg rt-PA total (10 mg given as a bolus followed by 50 mg, 20 mg and 20 mg per hour for 3 hours). These patients were monitored for t-PA antigen and t-PA activity and PAI-1 activity plasma levels during rt-PA infusion. Success or failure of thrombolytic therapy was evaluated by non-invasive criteria (early plasma creatine kinase peaks, early peak plasma myoglobin values, and electrocardiographic criteria) as well as by means of coronary angiography at the fourth day after thrombolytic treatment. In 24 (68.6%) of these patients a success of thrombolytic therapy could be established by these criteria, while 11 patients did not respond to thrombolytic therapy. Fifteen patients (14 responders and one non-responder) had to be excluded from the further evaluation because in these patients clinical laboratory data obtained upon admission before initiation of thrombolytic therapy were not complete. Therefore, 20 patients (10 responders and 10 non-responders) could further be analysed. The two groups of patients were not significantly different in body weight, body weight index, age, gender, liver or kidney functional parameters as determined before initiation of the thrombolytic therapy. Furthermore, PAI-1 plasma levels before initiation of thrombolytic therapy were not significantly different in the two groups, as were rt-PA dosage per body weight or body weight index. Only heart rate and calculated cardiac output and cardiac index were significantly higher in the group of patients not responsive to thrombolytic therapy. t-PA values, however, at 30, 60 and 90 min after initiation of rt-PA infusion were significantly higher in the group of responders as compared to the group of non-responders. From these data we conclude that cardiac output which in turn determines liver blood flow might lead to different t-PA plasma levels following the same rt-PA dosage and the resulting t-PA plasma level might determine success or failure of thrombolytic therapy in respect to reopening of the infarct-related vessel.

PDF (1062 kb)

References

References
1 GISSI-2. a factorial randomized trial of alteplase versus streptokinase and heparin versus no heparin among 12490 patients with acute myocardial infarction. Lancet 1990; 336: 67-70
2 ISIS-3. reported at a press conference preceding the American College of Cardiology Meeting in Atlanta. March 2 1991 (ISIS-3 Press release and preliminary report)
3 Collen D, Topol EJ, Tiefenbrunn AJ, Gold HK, Weisfeldt ML, Sobel BE, Leinbach RC, Briseker JA, Ludbrook PA, Yasuda I, Bulkley BH, Robison AK, Hutter AM, Bell WR, Spadaro JJ, Khaw BA, Grossbard EB. Coronary thrombolysis with recombinant human tissue-type plasminogen activator; a prospective, randomized, placebo-controlled trial. Circulation 1984; 70: 1012-1017
4 Verstraete M, Bory M, Collen D. Randomized trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Lancet 1985; 2: 842-847
5 Verstraete M, Bleifeld W, Brower RW, Charbonnier B, Collen D, DeBono DP, Dunning AJ, Lennane RJ, Lubsen J, Mathey DG, Michel PL, Raynaud PH, Schofer J, Vahanion A, Vahanecke J, Van De Kley GA, Van De Werf K, Von Essen R. Double-blind randomized trial of intravenous tissue-type plasminogen activator versus placebo in acute myocardial infarction. Lancet 1985; 2: 965-969
6 Passamani E, Hodges M, Herman M, Grose R, Chaitman B, Rogers W, Forman S, Terrin M, Knatterud G, Robertson T, Braunwald E. for the TIMI Investigators. The thrombolysis in myocardial infarction (TIMI) phase II pilot study: Tissue plasminogen activator followed by percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1987; 10: 51B-64B
7 Neuhaus K-L, Tebbe U, Gottwik M, Weber MAJ, Feuerer W, Niederer W, Haerer W, Praetorius F, Grosser K-D, Huhmann W, Hoepp H-W, Alber G, Sheikhzadeh A, Schneider B. Intravenous recombinant tissue plasminogen activator (rt-PA) and urokinase in acute myocardial infarction: results of the German Activator Urokinase Study (GAUS). J Am Coll Cardiol 1988; 12: 581-587
8 Topol EJ, Georg BS, Kereiakes DJ, Stump DC, Candela RJ, Abbothsmith CW, Aronson L, Pickel A, Boswick JM, Lee KL, Ellis SG, Califf RM. the TAMI Study Group. A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocaridal infarction. Circulation 1989; 79: 281-286
9 Van de Werf F. for the Investigators of the European Cooperative Study Group for Recombinant Tissue-Type Plasminogen Activator. Lessons from the European cooperative recombinant tissue-type plasminogen activator (rt-PA) versus placebo trial. J Am Coll Cardiol 1988; 12: 14A-19A
10 White HD, Rivers JT, Norris RM, Takayama M, Maslowski A, Hart H, Sharpe N, Ormiston J. Is RT-PA or streptokinase superior for preservation of left ventricular function after myocardial infarction?. Circulation 1988; 78 (Suppl. 02) 303
11 Hughenholtz PG. Acute coronary artery obstruction in myocardial infarction: overview of thrombolytic therapy. J Am Coll Cardiol 1987; 9: 1375-1384
12 Hlatky MA, Cotugno H, O’Connor C, Mark DB, Pryor DB, Califf RM. Adoption of thrombolytic therapy in the management of acute myocardial infarction. Am J Cardiol 1988; 61: 510-514
13 Mathey DG, Schofer J, Bleifeld W. Zeitabhängigkeit der Myokarderhaltung nach Thrombolyse. Dtsch Med Wschr 1985; 110: 1681-1685
14 Turi ZG, Stone PH, Muller JE, Posker C, Rude RE, Raabe DE, Jaffe AS, Hartwell TD, Robertson TL, Braunwald E. The MILIS Study Group. Implications for acute intervention related to time of hospital arrival in acute myocardial infarction. Am J Cardiol 1986; 58: 203-209
15 Gold HK, Fallon JT, Yasuda T, Leinbach RC, Khaw BA, Newell JB, Guerrero JL, Vislosky FM, Hoyng CF, Grossbard E. Collen DCoronary thrombolysis with recombinant human tissue-type plasminogen activator. Circulation 1984; 70: 700-707
16 Garabedian HD, Gold HK, Leinbach RC, Yasuda T, Johns JA, Collen D. Dosedependent thrombolysis, pharmacokinetics and haemostatic effects of recombinant human tissue-type plasminogen activator for coronary thrombosis. Am J Cardiol 1986; 58: 673-679
17 Clozel J-P, Tschopp T, Luedin E, Holvoet P. Time course of thrombolysis induced by intravenous bolus or infusion of tissue plasminogen activator in a rabbit jugular vein thrombosis model. Circulation 1989; 79: 125-133
18 Collen D, Bounameaux H, De Cock F, Lijnen HR, Verstraete M. Analysis of coagulation and fibrinolysis during intravenous infusion of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction. Circulation 1986; 73: 511-517
19 Neuhaus K-L, Feuerer W, Jepp-Tebbe S, Niederer W, Vogt A, Tebbe U. Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activator. JACC 1989; 14: 1566-1569
20 Gore JM, Roberts R, Alfredo M, Ball SP, Manteno A, Goldberg RJ. Peak creatine kinase as a measure of the effectiveness of thrombolytic therapy in acute myocardial infarction. Am J Cardiol 1987; 59: 1234-1238
21 Garabedian HD, Gold HK, Yasuda T, Johns JA, Finkelstein DM, Galvin RJ, Cobbaert C, Leinbach RC, Collen D. Detection of coronary artery reperfusion with creatine kinase – MB determinations during thrombolytic therapy: correlation with acute angiography. J Am Coll Cardiol 1988; 11: 729-734
22 Kircher BJ, Topol EJ, O’Neill WW, Bertram B. Prediction of infarct coronary artery recanalization after intravenous thrombolytic therapy. Am J Cardiol 1987; 59: 513-515
23 Ellis AK, Little T, Masud ARZ, Liberman HA, Morris DC, Klocke FJ. Early noninvasive detection of successful reperfusion in patients with acute myocardial infarction. Circulation 1988; 78: 1352-1357
24 Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen J, Dodge HT, Francis CK, Hillis D, Ludbrook P, Markis JE, Mueller H, Passamani ER, Powers ER, Rao AK, Robertson T, Ross A, Ryan TJ, Sobel BE, Willerson J, Williams DO, Zoset BL, Braunwald E. Thrombolysis in myocardial infarction (TIMI) trial: Phase I. A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation 1987; 76: 142-154
25 Wojta J, Turcu L, Wagner OF, Korninger C, Binder BR. Evaluation of fibrinolytic capacity by a combined assay system for t-PA antigen and t-PA function using monoclonal anti-t-PA antibodies. J Lab Clin Med 1987; 109: 665-671
26 Korninger C, Wagner O, Binder BR. Tissue plasminogen activator inhibitor in human plasma: development of a functional assay system and demonstration of a correlating Mr 50,000 antiactivator. J Lab Clin Med 1985; 105: 718-724
27 Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Basel: Acta Haematol 1957; 17: 237-246
28 Berne RM, Levy MN. Cardiovascular Physiology. Mosby, St. Louis, MO 1977
29 Korninger C, Stassen JM, Collen D. Turnover of human extrinsic (tissue-type) plasminogen activator in rabbits. Thromb Haemostas 1981; 46: 658-661
30 Verstraete M, Bounameaux H, De Cock F, van de Werf F, Collen D. Pharmacokinetics and systemic fibrinolytic effects of recombinant human tissue-type plasmainogen activator (rt-PA) in man. J Pharmacol Exp Ther 1985; 235: 506-512
31 Rijken DC, Emais JJ. Clearance of the heavy and light polypeptide chains of human tissue-type plasminogen activator in rats. Biochem J 1986; 238: 643-646
32 Bakhit CS, Lewis D, Busch U, Tanswell P, Mohler M. Biodisposition and catabolism of tissue-type plasminogen activator in rats and rabbits. Fibrinolysis 1988; 2: 31-36
33 Tanswell P, Schlüter M, Krause J. Pharmacokinetics and isolated lower perfusion of carbohydrate-modified recombinant tissue-type plasminogen activator. Fibrinolysis 1989; 3: 79-84
34 Krause J. Catabolism of tissue-type plasminogen activator (t-PA), its variants, mutants and hybrids. Fibrinolysis 1988; 2: 133-142
35 de Boer A, Kluft C, Kroon JM, Kaspar FJ, Schoemaker HC, Pruis I, Breimer BD, Soons PA, Emeis J, Cohen AF. Liver blood flow as a major determinant of the clearance of recombinant human tissue-type plasminogen activator. Thromb Haemostas 1992; 67: 83-87
36 Huber K, Kirchheimer JC, Korninger C, Binder BR. Hepatic synthesis and clearance of components of the fibrinolytic system in healthy volunteers and in patients with different stages of liver cirrhosis. Thromb Res 1991; 62: 491-500
37 Ruben A, Zito MD, Reid PR. Lidocaine kinetics predicted by indocyanine green clearance. N Engl J Med 1978; 298: ll60-ll63
38 Roberts S, Rogers WJ, Mueller HS, Labrew CT, Diver DJ, Smith HC, Willerson JT, Knatterud GL, Foreman S, Passamani E, Zaret BL, Wackers FJT, Braunwald E. for the TIMI Investigators. Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction: Results of the thrombolysis in myocardial infarction (TIMI) II-B Study. Circulation 1991; 83: 422-437